Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Non-Small Cell Lung Cancer
Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing organs in the chest. The lungs bring oxygen into the body as you breathe in. They release carbon dioxide,a waste product of the body’s cells,as you breathe out. Each lung has sections called lobes. The left lung has two lobes. The right ..
Malignant Mesothelioma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (07 / 16 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Limited-Stage Small Cell Lung Cancer Treatment
Standard Treatment Options for Patients With Limited-Stage Small Cell Lung Cancer (SCLC)Standard treatment options for patients with limited-stage SCLC include the following:Chemotherapy and radiation therapy.Combination chemotherapy alone.Surgery followed by chemotherapy or chemoradiotherapy.Prophylactic cranial irradiation.Chemotherapy and radiation therapyCombined-modality treatment with etoposide and cisplatin with thoracic radiation therapy (TRT) is the most widely used treatment for patients with limited-stage disease (LD) SCLC.Evidence (combined modality treatment):Survival. The following results have been reported in clinical trials:Mature results of prospective randomized trials suggest that combined-modality therapy produces a modest but significant improvement in survival of 5% at 3 years compared with chemotherapy alone.[1,2,3][Level of evidence: 1iiA]Clinical trials have consistently achieved median survivals of 18 to 24 months and 40% to 50% 2-year survival
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Extensive-Stage Small Cell Lung Cancer Treatment
Standard Treatment Options for Patients With Extensive-Stage Small Cell Lung Cancer (SCLC)Standard treatment options for patients with extensive-stage SCLC include the following:Combination chemotherapy.Radiation therapy.Prophylactic cranial irradiation.Combination chemotherapyChemotherapy for patients with extensive-stage disease (ED) SCLC is commonly given as a two-drug combination of platinum and etoposide in doses associated with at least moderate toxic effects (as in limited-stage [LD] SCLC). Cisplatin is associated with significant toxic effects and requires fluid hydration, which can be problematic in patients with cardiovascular disease. Carboplatin is active in SCLC, is dosed according to renal function, and is associated with less nonhematological toxic effects.Other regimens appear to produce similar survival outcomes but have been studied less extensively or are in less common use.Table 2. . Combination Chemotherapy For Extensive-Stage Small Cell
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage 0 NSCLC Treatment
Stage 0 NSCLC frequently progresses to invasive cancer.[1,2,3] Patients may be offered surveillance bronchoscopies and, if lesions are detected, potentially curative therapies.Standard Treatment Options for Stage 0 NSCLCStandard treatment options for stage 0 NSCLC include the following:Surgery.Endobronchial therapies, including photodynamic therapy, electrocautery, cryotherapy, and Nd-YAG laser therapy.SurgerySegmentectomy or wedge resection are used to preserve maximum normal pulmonary tissue since patients with stage 0 NSCLC are at a high risk for second lung cancers. Because these tumors are by definition noninvasive and incapable of metastasizing, they should be curable with surgical resection; however, such lesions, when identified, are often centrally located and may require a lobectomy. Endobronchial therapiesPatients with central lesions may be candidates for curative endobronchial therapy. Endobronchial therapies that preserve lung function include photodynamic therapy,
Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for NSCLC
BackgroundIn NSCLC, the determination of stage is important in terms of therapeutic and prognostic implications. Careful initial diagnostic evaluation to define the location and to determine the extent of primary and metastatic tumor involvement is critical for the appropriate care of patients. In general, symptoms, physical signs, laboratory findings, or perceived risk of distant metastasis lead to an evaluation for distant metastatic disease. Additional tests such as bone scans and computed tomography (CT)/magnetic resonance imaging (MRI) of the brain may be performed if initial assessments suggest metastases or if patients with stage III disease are under consideration for aggressive local and combined modality treatments.Stage has a critical role in the selection of therapy. The stage of disease is based on a combination of clinical factors and pathological factors. The distinction
Lung Cancer Screening (PDQ®): Screening - Patient Information [NCI] - What is screening?
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early,it may be easier to treat. By the time symptoms appear,cancer may have begun to spread. Scientists are trying to better understand which people are more likely to get certain types of cancer. They also study the things we do and the ...
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062945-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Small Cell Lung Cancer Treatment
Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Small Cell Lung Cancer Treatment
Standard Treatment Options for Patients With Recurrent Small Cell Lung Cancer (SCLC)Standard treatment options for patients with recurrent SCLC include the following:Chemotherapy.Palliative therapy.At the time of recurrence, many SCLC patients are potential candidates for further therapy.ChemotherapyAlthough second-line chemotherapy has been shown to produce tumor regression, responses are usually short lived; the median survival is rarely more than 12 months and usually less than 6 months after second-line therapy. Response to first-line chemotherapy predicts for subsequent response to second-line therapy.As in other chemosensitive tumors (e.g., Hodgkin lymphoma and ovarian epithelial cancer), two main categories of patients receiving second-line chemotherapy have been described: sensitive and resistant. Sensitive patients have a first-line response that lasted more than 90 days after treatment was completed. These patients have the greatest benefit from second-line chemotherapy.